<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336660</url>
  </required_header>
  <id_info>
    <org_study_id>XM-10/02</org_study_id>
    <nct_id>NCT01336660</nct_id>
  </id_info>
  <brief_title>A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco</brief_title>
  <official_title>Phase 2/3 Study for Scorpion North Africa Middle East Envenomation With a Immune F(ab')2 (Equine) Antivenom Alacramyn NAMO. A Randomized, Double-Blind, Placebo-controlled, Prospective and Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bioclon S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Antipoison et de Pharmacovigilane du Maroc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Pasteur du Maroc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Bioclon S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has the objective to demonstrate the effectiveness of Alacramyn NAMO in the
      treatment of North Africa and Middle East scorpions envenomation by reducing the severity of
      envenomation. The primary endpoint is make a comparison between antivenom and placebo groups,
      at 4 hours after study drug, of the number of cases showing improvement in class of
      envenomation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an effort to shorten hospital stay and to further decrease mortality, a new antivenom has
      been developed. This antivenom is a third generation F(ab')2 &quot;fabotherapeutic&quot; agent.It is
      administered intravenously which should lead to rapid neutralization of circulating venom.
      This study will demonstrate whether or not use of the new antivenom in children receiving
      standardized supportive care leads to resolution of the syndrome within 4 hours of
      treatment.The onset of clinical symptoms following a scorpion envenomation is usually within
      5 to 30 minutes following the sting.

      Established a classification of the patient status to differentiate a simple scorpion sting
      from a severe envenomation. A simple sting (class I) is characterized by signs that are local
      only: pain at the inoculation point, redness, edema, and numbness.

      A class II envenomation is characterized by the presence of some systemic signs: hypothermia,
      hyperthermia, chills, nausea, abdominal pain and diarrhea. Being 15 years old or younger or
      the presence of priapism, vomiting, sweating, or a body temperature greater than 39°C are
      factors predictive of severity.

      A severe envenomation (class III) is characterized by cardiovascular failure, often leading
      to death; respiratory failure related to the cardiac failure; and neurologic failure due to
      hypoxia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate the effectiveness of Alacramyn NAMO in the treatment of scorpion envenomation by reducing the severity of envenomation</measure>
    <time_frame>4 hours after study drug</time_frame>
    <description>Comparison between antivenom and placebo groups of the number of cases showing improvement in class of envenomation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Alacramyn NAMO in the treatment of scorpion envenomation by reducing the severity of envenomation.</measure>
    <time_frame>To 16 hours after treatment until discharge time and date</time_frame>
    <description>Decrease in plasma venom levels from baseline to one hour after study drug administration; Respiratory rate (breaths per minute); Heart rate (beats per minute); Dose of dobutamine (cumulative, per hour);Incidence of cardiac failure; Incidence of ventilatory failure; Incidence of neurological failure; Mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Poisoning by Scorpion Sting</condition>
  <arm_group>
    <arm_group_label>Equine F(ab')2 antivenom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive care support and Equine F(ab')2 antivenom</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intensive care support plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Equine F(ab')2 antivenom</intervention_name>
    <description>A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute</description>
    <arm_group_label>Equine F(ab')2 antivenom</arm_group_label>
    <other_name>Alacramyn NA</other_name>
    <other_name>Scorpion North Africa and Middle East Immune F(ab')2(Equine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intensive care support plus placebo</intervention_name>
    <description>Intensive care support as needed plus placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 6 months to 15 years

          -  Class II B or III scorpion envenomation

          -  Presenting within 5 hours of sting

          -  Informed consent read and signed by parent or legal guardian

        Exclusion Criteria:

          -  Unable to provide informed consent

          -  Prior use of antivenom for this envenomation

          -  Allergy to horse serum

          -  Pregnant or breast-feeding

          -  Patients with underlying condition mimicking symptoms of scorpion envenomation
             (congenital heart disease, chronic oxygen therapy, etcetera)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Garcia, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Bioclon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rachida Soulaymani, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Antipoison et de Pharamacovigilance du Maroc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanae Achour</last_name>
    <role>Principal Investigator</role>
    <affiliation>FES University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asmae Khattabi</last_name>
    <role>Study Chair</role>
    <affiliation>Ecole Nationale de Santé Publique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walter Garcia, MD</last_name>
    <phone>0052 (1) 55 3733 3630</phone>
    <email>wgarcia@silanes.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachida Soulaymani, MD</last_name>
    <phone>00212537777169</phone>
    <email>rsoulaymani@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Hassan II de Fès</name>
      <address>
        <city>Fès</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harrandou Mustapha, MD</last_name>
      <email>harandoumustapha@yahoo.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sanae Achour, Pr</last_name>
      <phone>2120661421282</phone>
      <email>achour_sanae@yahoo.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Harrandou Mustapha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Ibn Zohr, Marrakech</name>
      <address>
        <city>Marrakech</city>
        <country>Morocco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zakar Abdelkader, MD</last_name>
      <phone>212661490544</phone>
      <email>abdele_zakar@hotmail.fr</email>
    </contact>
    <investigator>
      <last_name>Zakar Abdelkader, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Morocco</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness</keyword>
  <keyword>New Antivenom</keyword>
  <keyword>North Africa and Middle East Scorpio Envenomation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poisoning</mesh_term>
    <mesh_term>Scorpion Stings</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antivenins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>not yet decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

